Companies: 10,795·Total market cap: $144.5T
Novo Nordisk A/S

Novo Nordisk A/S

NVONYSEHealthcare● Active
$42.96
$-0.79(-1.81%)
Market Cap$190.9B
P/E Ratio—
52W High$81.44
52W Low$35.12
Overview

Novo Nordisk A/S (NVO) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

NVO · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$26.96B▲ +2.5% vs prior year
FY · as of Dec 31, 2025 · Reported in DKK
Cash & Cash Equiv. (CCE)
$26.46B
cashAndCashEquivalents
Short-Term Investments
$498.0M
shortTermInvestments
YoY Change vs Prior Year
+2.5%
vs prior fiscal year
Latest Quarter
$21.63B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in DKK

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$26.96BCash on Hand
Total Debt$130.96BTotal Debt
Net Cash / Net Debt−$104.00BNet Debt Position
Cash vs Debt Ratio
Cash 17%Debt 83%

Novo Nordisk A/S carries a net debt position of $104.00B. Total debt ($130.96B) exceeds cash on hand ($26.96B). Novo Nordisk A/S cash vs debt ratio: 17% cash / 83% debt.

Net Cash = Cash & ST Investments − Total Debt$26.96B − $130.96B = −$104.00B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
NVO annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$26.96B+2.5%
Dec 31, 2024$26.31B-13.0%
Dec 31, 2023$30.23B+28.2%
Dec 31, 2022$23.57B+34.8%
Dec 31, 2021$17.48B+733.8%
NVO cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%
#2
Novo Nordisk A/S
Novo Nordisk A/SYOU
NVO
$26.96B14.1%
#3
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#4
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Novo Nordisk A/S (NVO) cash on hand as of December 31, 2025 is $26.96B, comprising $26.46B in cash and cash equivalents (CCE) plus $498.0M in short-term investments — reported as Novo Nordisk A/S cash and short-term investments on the balance sheet (10-K filing). Also referred to as Novo Nordisk A/S cash reserves or cash position.

Novo Nordisk A/S annual cash on hand history shows increased +2.5% in 2025: increased +2.5% in 2025. Novo Nordisk A/S cash reserves in 2025 reflect the company's capital allocation strategy.

Novo Nordisk A/S carries total debt of $130.96B against cash of $26.96B, resulting in a net debt position of -$104.00B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

NVO cash on hand · 5 questions

As of December 31, 2025, Novo Nordisk A/S (NVO) has $26.96B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $26.46B in cash and cash equivalents (CCE) plus $498,000,000 in short-term investments. Latest quarter (March 31, 2026): $21.63B. Data sourced from the annual 10-K filing via FMP.

NVO cash on handNVO cash reservesNVO cash 2025how much cash does NVO have

▸ Source: FMP /balance-sheet-statement · US GAAP · Novo Nordisk A/S · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025